These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21051744)

  • 1. Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients.
    Fioretto P; Najafian B; Sutherland DE; Mauer M
    Clin J Am Soc Nephrol; 2011 Jan; 6(1):101-6. PubMed ID: 21051744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
    Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
    Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
    Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
    Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor nephrotoxicity.
    Naesens M; Kuypers DR; Sarwal M
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):481-508. PubMed ID: 19218475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation.
    Yessayan L; Shafiq A; Peterson E; Wells K; Hu Y; Williams LK; Lanfear D
    Transplant Proc; 2015 Dec; 47(10):2968-72. PubMed ID: 26707323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Magnesium and Related Factors in Long-Term Renal Transplant Recipients: An Observational Study.
    Rodrigues N; Santana A; Guerra J; Neves M; Nascimento C; Gonçalves J; da Costa AG
    Transplant Proc; 2017 May; 49(4):799-802. PubMed ID: 28457398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
    Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
    Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors.
    Niel OR; Berthoux F; Albano L; Dahan P; Aoudia R; Gugenheim J; Cassuto E
    Transplant Proc; 2009 Oct; 41(8):3329-32. PubMed ID: 19857743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors].
    Nikitin AV
    Antibiot Khimioter; 2014; 59(1-2):44-7. PubMed ID: 25051716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects.
    Klein IH; Abrahams A; van Ede T; Hené RJ; Koomans HA; Ligtenberg G
    Transplantation; 2002 Mar; 73(5):732-6. PubMed ID: 11907418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
    Zaltzman JS
    Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation.
    Morales JM; Andres A; Rengel M; Rodicio JL
    Nephrol Dial Transplant; 2001; 16 Suppl 1():121-4. PubMed ID: 11369839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.